Inovio Pharmaceuticals (INO) Current Assets (2010 - 2026)
Inovio Pharmaceuticals (INO) posted Current Assets of $39.4 million for Q1 2026, down 35.48% sequentially from $61.1 million in Q4 2025, and down 45.14% YoY from $71.9 million in Q1 2025.
Inovio Pharmaceuticals (INO) Current Assets (2010 - 2026) Analysis & Trends
Inovio Pharmaceuticals has reported Current Assets for 17 years, with the latest figure at $39.4 million in Q1 2026.
- Quarterly Current Assets fell 45.14% year-over-year to $39.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.4 million (down 45.14% YoY) and the FY2025 annual result came in at $61.1 million, down 37.52% from the prior year.
- Current Assets eased to $39.4 million in Q1 2026 per INO's latest filing, from $61.1 million in the prior quarter.
- Over five years, Current Assets peaked at $416.2 million in Q2 2022 and troughed at $39.4 million in Q1 2026.
- A 5-year average of $173.3 million and a median of $117.6 million in 2024 frame the typical range for Current Assets.
- The sharpest annual moves came in 2022 and 2025: Current Assets slipped 23.27% in 2022, then sank 55.17% in 2025.
- Over 5 years, Current Assets stood at $315.2 million in 2022, then tumbled by 51.43% to $153.1 million in 2023, then slumped by 36.11% to $97.8 million in 2024, then sank by 37.52% to $61.1 million in 2025, then plunged by 35.48% to $39.4 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $39.4 million, $61.1 million, and $55.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Inovio Pharmaceuticals | 96.32 Mn | 96.32 Mn | - | 39.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.91 Mn |
| Mar 31, 2026 | 39.44 Mn |
| Dec 31, 2025 | 61.12 Mn |
| Sep 30, 2025 | 55.18 Mn |
| Jun 30, 2025 | 52.70 Mn |
| Mar 31, 2025 | 71.89 Mn |
| Dec 31, 2024 | 97.83 Mn |
| Sep 30, 2024 | 91.28 Mn |
| Jun 30, 2024 | 117.56 Mn |
| Mar 31, 2024 | 111.68 Mn |
| Dec 31, 2023 | 153.11 Mn |
| Sep 30, 2023 | 174.77 Mn |
| Jun 30, 2023 | 203.28 Mn |
| Mar 31, 2023 | 233.90 Mn |
| Dec 31, 2022 | 315.24 Mn |
| Sep 30, 2022 | 350.21 Mn |
| Jun 30, 2022 | 416.19 Mn |
| Mar 31, 2022 | 399.91 Mn |
| Dec 31, 2021 | 448.44 Mn |
| Sep 30, 2021 | 487.40 Mn |